研究者詳細 - 尾﨑　敏文

論文 - 尾﨑　敏文

分割表示 1,743 件中 261 - 280 件目／全件表示 >>

鏡視下手根管開放術と小切開手根管開放術の短期成績の比較検討

中道亮, 斎藤太一, 島村安則, 尾崎敏文

日本手外科学会雑誌 40 ( 1 ) O25 - 2 2023年4月

弾発指に対する術後リハビリテーションの有効性

斎藤太一, 中道亮, 島村安則, 西田圭一郎, 尾崎敏文

日本手外科学会雑誌 40 ( 1 ) O32 - 2 2023年4月

野球選手における有鉤骨骨折に対する皮皺に沿った掌側進入法における手術治療成績

島村安則, 根津智史, 斎藤太一, 中道亮, 山脇正, 久禮美穂, 西田圭一郎, 尾崎敏文

日本手外科学会雑誌 40 ( 1 ) O38 - 5 2023年4月

内側半月板後根プルアウト修復術後の外側楔状足底板の使用は術後成績を改善する

川田紘己, 古松毅之, 横山裕介, 金高圭甫, 東原直裕, 田村優典, 尾崎敏文

中国・四国整形外科学会雑誌 35 ( 1 ) 186 - 186 2023年4月

片側下腿に発生した多発性グロムス腫瘍の一例査読

徳田貴大, 藤原智洋, 近藤彩奈, 国定俊之, 中田英二, 西村碧フィリーズ, 柳井広之, 尾崎敏文

中国・四国整形外科学会雑誌 35 ( 1 ) 47 - 51 2023年4月

記述言語：日本語出版者・発行元：中国・四国整形外科学会

症例は21歳男性で、左下腿脛骨外側部のグロムス腫瘍切除術後2ヵ月経過した時点で左下腿の疼痛が再燃した。MRIでは左脛骨前面、脛骨後面、脛腓間、腓骨周囲に多発性の腫瘤を認め、これら全病変を辺縁切除した。病理検査では全てグロムス腫瘍と診断され、術後1年の時点で疼痛の再燃や腫瘍の再発は認めず、趣味のダンスも再開している。

researchmap

重度骨粗鬆症性椎体骨折に対するCement catching screwの有用性

三澤治夫, 魚谷弘二, 小田孔明, 志渡澤央和, 植田昌敬, 尾崎敏文

Journal of Spine Research 14 ( 3 ) 680 - 680 2023年4月

Lenke type 1思春期特発性側彎症におけるHybrid法とSegmental Pedicle screw法による治療効果の検討

魚谷弘二, 三澤治夫, 鉄永倫子, 小田孔明, 志渡澤央和, 植田昌敬, 尾崎敏文

Journal of Spine Research 14 ( 3 ) 283 - 283 2023年4月

骨粗鬆症治療を導入すべき脊椎手術を受ける患者の現状

高尾真一郎, 三澤治夫, 小田孔明, 魚谷弘二, 鉄永倫子, 山根健太郎, 竹内一裕, 尾崎敏文, 中原進之介

Journal of Spine Research 14 ( 3 ) 651 - 651 2023年4月

Malignant spinal Cord Compression(MSCC)を伴う転移性脊椎腫瘍患者に対する手術介入は生命予後を改善するのか

志渡澤央和, 魚谷弘二, 三澤治夫, 鉄永倫子, 小田孔明, 植田昌敬, 尾崎敏文

Journal of Spine Research 14 ( 3 ) 243 - 243 2023年4月

内側半月板後根プルアウト修復術後の外側楔状足底板の使用は術後成績を改善する

川田紘己, 古松毅之, 横山裕介, 金高圭甫, 東原直裕, 田村優典, 尾崎敏文

中国・四国整形外科学会雑誌 35 ( 1 ) 186 - 186 2023年4月

Meniscus extrusion is a predisposing factor for determining arthroscopic treatments in partial medial meniscus posterior root tears. 国際誌

Takayuki Furumatsu, Keisuke Kintaka, Naohiro Higashihara, Masanori Tamura, Koki Kawada, Haowei Xue, Toshifumi Ozaki

Knee surgery & related research 35 ( 1 ) 8 - 8 2023年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Patients with partial medial meniscus posterior root tears (MMPRTs) sometimes require arthroscopic pullout repair because of their intolerable/repeated knee pains and continuous disturbance in gait during activities of daily living. However, the predisposing factors for future knee surgery in patients with partial MMPRTs remain unclear. We compared the findings of magnetic resonance imaging (MRI) between patients who underwent pullout repair and nonoperative management following partial MMPRTs. METHODS: Twenty-five patients who required arthroscopic repair for partial MMPRTs and 23 patients who were managed nonoperatively were evaluated during a mean follow-up period of 27.1 months. Sex, age, height, body weight, body mass index, duration from onset to initial MRI, MRI findings, and medial meniscus (MM) extrusion were compared between the two groups. Linear regression analysis was used to assess the correlation between MM extrusion and duration from onset to MRI examination. RESULTS: No significant differences were observed between the pullout repair and nonoperative management groups in terms of patient demographics and the positive ratio of MRI-based root tear signs. However, absolute MM extrusion in the pullout repair group (3.49 ± 0.82 mm) was larger than that in the nonoperative management group (2.48 ± 0.60 mm, P < 0.001). Extrusion of the MM (> 3 mm) was detected more frequently in the pullout repair group than in the nonoperative management group (P < 0.001). The odds ratio in the pullout repair and MM extrusion > 3 mm cases was 9.662. Linear regression analysis revealed a fair correlation between the duration from onset to MRI and MM extrusion only in the pullout repair group (0.462 mm/month increase in MM extrusion). CONCLUSIONS: This study demonstrated that more severe MM extrusions were observed in the pullout repair group than in the nonoperative management group. Major extrusion (> 3 mm) was also observed more in the pullout repair group than in the nonoperative group. Assessing MM extrusion and its severity can help determine a valid treatment for patients with partial MMPRTs. LEVEL OF EVIDENCE: IV, Retrospective comparative study.

DOI： 10.1186/s43019-023-00182-6

PubMed

researchmap

Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib. 国際誌

Makoto Endo, Tomoko Kataoka, Toshifumi Fujiwara, Satoshi Tsukushi, Masanobu Takahashi, Eisuke Kobayashi, Yoko Yamada, Takaaki Tanaka, Yutaka Nezu, Hiroaki Hiraga, Junji Wasa, Akihito Nagano, Kenji Nakano, Robert Nakayama, Tetsuya Hamada, Masanori Kawano, Tomoaki Torigoe, Akio Sakamoto, Kunihiro Asanuma, Takeshi Morii, Ryunosuke Machida, Yuta Sekino, Haruhiko Fukuda, Yoshinao Oda, Toshifumi Ozaki, Kazuhiro Tanaka

BMC cancer 23 ( 1 ) 219 - 219 2023年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Soft tissue sarcomas (STS) are a rare type of malignancy comprising a variety of histological diagnoses. Chemotherapy constitutes the standard treatment for advanced STS. Doxorubicin-based regimens, which include the administration of doxorubicin alone or in combination with ifosfamide or dacarbazine, are widely accepted as first-line chemotherapy for advanced STS. Trabectedin, eribulin, pazopanib, and gemcitabine plus docetaxel (GD), which is the empirical standard therapy in Japan, are major candidates for second-line chemotherapy for advanced STS, although clear evidence of the superiority of any one regimen is lacking. The Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group (JCOG) conducts this trial to select the most promising regimen among trabectedin, eribulin, and pazopanib for comparison with GD as the test arm regimen in a future phase III trial of second-line treatment for patients with advanced STS. METHODS: The JCOG1802 study is a multicenter, selection design, randomized phase II trial comparing trabectedin (1.2 mg/m2 intravenously, every 3 weeks), eribulin (1.4 mg/m2 intravenously, days 1 and 8, every 3 weeks), and pazopanib (800 mg orally, every day) in patients with unresectable or metastatic STS refractory to doxorubicin-based first-line chemotherapy. The principal eligibility criteria are patients aged 16 years or above; unresectable and/or metastatic STS; exacerbation within 6 months prior to registration; histopathological diagnosis of STS other than Ewing sarcoma, embryonal/alveolar rhabdomyosarcoma, well-differentiated liposarcoma and myxoid liposarcoma; prior doxorubicin-based chemotherapy for STS, and Eastern Cooperative Oncology Group performance status 0 to 2. The primary endpoint is progression-free survival, and the secondary endpoints include overall survival, disease-control rate, response rate, and adverse events. The total planned sample size to correctly select the most promising regimen with a probability of > 80% is 120. Thirty-seven institutions in Japan will participate at the start of this trial. DISCUSSION: This is the first randomized trial to evaluate trabectedin, eribulin, and pazopanib as second-line therapies for advanced STS. We endeavor to perform a subsequent phase III trial comparing the best regimen selected by this study (JCOG1802) with GD. TRIAL REGISTRATION: This study was registered with the Japan Registry of Clinical Trials ( jRCTs031190152 ) on December 5, 2019.

DOI： 10.1186/s12885-023-10693-w

PubMed

researchmap

腱滑膜巨細胞腫に対するザルトプロフェンのプラセボ対照無作為化二重盲検比較試験(第II相試験) The REALIZE study

武内章彦, 遠藤誠, 川井章, 西田佳弘, 寺内竜, 松峯昭彦, 相羽久輝, 中村知樹, 丹代晋, 尾崎敏文, 土屋弘行

日本整形外科学会雑誌 97 ( 2 ) S88 - S88 2023年3月

悪性末梢神経鞘腫瘍におけるPRRX1の治療標的分子としての可能性

たき平将太, 中田英二, 大曽根達則, 山田大祐, 高尾知佳, 佐藤浩平, 畑利彰, 藤原智洋, 国定俊之, 宝田剛志, 尾崎敏文

日本整形外科学会雑誌 97 ( 3 ) S1040 - S1040 2023年3月

[Ⅲ. The Role of Comprehensive Genomic Profiling in Sarcoma].

Eiji Nakata, Tomohiro Fujiwara, Toshiyuki Kunisada, Toshifumi Ozaki, Shinichi Toyooka, Daisuke Ennishi, Hideki Yamamoto, Kiichiro Ninomiya, Shuta Tomida, Akira Hirasawa, Mashu Futagawa, Masahiro Tabata

Gan to kagaku ryoho. Cancer & chemotherapy 50 ( 3 ) 314 - 320 2023年3月